Head-to-head · Cost-Efficiency Index
Hims & Hers vs bmiMD
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Hims & Hers
People who want a familiar, app-driven consumer brand and only need semaglutide.
Visit Hims & HersbmiMD
Price-driven shoppers who want both molecules cheap and nationwide, with a real month-to-month option if they don't want to prepay a year.
Visit bmiMDThe verdict
Hims & Hers takes it, leading the Cost-Efficiency Index 83 to 82. Nationwide reach and a slick app at a mid-market semaglutide price — but an undisclosed tirzepatide price leaves part of the value equation blank. bmiMD still earns a B− — Price-driven shoppers who want both molecules cheap and nationwide, with a real month-to-month option if they don't want to prepay a year.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Hims & Hers.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Hims & Hers | bmiMD |
|---|---|---|
| Cost-Efficiency Index | 83/100 | 82/100 |
| Semaglutide / mo | $199/mo | $129/mo (true month-to-month; $99/mo requires 12-mo prepay) |
| Tirzepatide / mo | Not disclosed | $179/mo (true month-to-month; $139/mo requires 12-mo prepay) |
| Semaglutide / yr (modeled) | $2,388 | $1,548 |
| Tirzepatide / yr (modeled) | — | $2,148 |
| Coverage | All 50 states | All 50 states |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #22 | #24 |
Hims & Hers
83/100Where the value is
- Nationwide
- Slick app experience
- Semaglutide priced up front for modeling
The tradeoffs
- Tirzepatide pricing not consistently disclosed
- Compounded supply has drawn industry-wide regulatory scrutiny
Regulatory note: the FDA issued a warning letter to Hims & Hers Health, Inc. dba Hims in September 2025. We still list and link to Hims & Hers; you should know the letter is on the public record before you decide.
bmiMD
82/100Where the value is
- Low prices on both molecules even month-to-month — $129 semaglutide / $179 tirzepatide, with no dose-based escalation
- A genuine no-commitment month-to-month option exists alongside the cheaper prepay tiers, unlike sites that gate pricing entirely behind a term
- Nationwide all-50 access with both molecules disclosed
The tradeoffs
- The advertised $99/$139 headline requires a full 12-month prepay ($1,188/$1,668 paid upfront) — the true month-to-month rate is 29-30% higher
- Compounded only — no oral or brand option
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.